All News
COVID: DMARDs, Steroids, a Vaccine - and how long will this continue?
Dr. Kevin Winthrop reviews all things COVID-related including abstract L01 from the 2020 ACR Convergence, steroids and DMARDs, vaccination status - and how long this pandemic will last.
Read Article
COVID and Rheumatic Disease Patients: Dr. Kevin Winthrop
Portland-based Dr. Kevin Winthrop from OHSU discusses Saturday ACR 2020 posters #0623 and #0629 related to COVID-19 and rheumatic disease patients.
Read Article
Answering questions on how COVID-19 affects rheumatic patients
As we inch closer to a possible vaccine for COVID-19, we are finally filling in the details on how the pandemic is affecting every aspect of our patient’s lives.
Read Article
A Convergence of Ideas: COVID19 and ACR by Dr. Kathryn Dao (@KDAO2011) #ACR20 https://t.co/95Y3ilCwyq https://t.co/Oje9vcbHnt
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch our video titled "Outcomes for Rheumatic Disease Patients with COVID-19" with Dr Kathryn Dao ( @KDAO2011) #ACR20
https://t.co/771RLB0pqA https://t.co/glr98MQHac
Links:
Dr. John Cush RheumNow ( View Tweet)
Telemedicine Studies: A Trainee’s Perspective by Mrinalini Dey ( @DrMiniDey ) COVID-19 has shifted face to face to consultations--an important change in rheumatology practice. #ACR20 https://t.co/IzvyeFC8w8 https://t.co/SIQxfuUuEk
Links:
Dr. John Cush RheumNow ( View Tweet)
Moderna mRNA-1273 vaccine, developed for COVID-19, yielded 94.5% efficacy in early results of the phase 3 COVE trial. 90 who were COVID-19 pos were in a placebo group and that 5 patients were in the mRNA-1273 vaccine group. https://t.co/9245wj3kph
Links:
Dr. John Cush RheumNow ( View Tweet)
AI, COVID and metabolomics are among the top subjects Dr. Arthur Kavanaugh previews in this opening perspective of #ACR20.
https://t.co/rE4uPDGRUK https://t.co/ei00a1jw2B
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Janet Pope ( @Janetbirdope) meets with several rheumatology trainees to discuss training and education in this COVID-19 era. Interviewees includes Drs. Arpat Gantayet, Gabriel Jeyasingham, Gemma Cramarossa and Melissa Holdren. #ACR20
https://t.co/YSitDviOon https://t.co/NGWaEtzyMR
Links:
Dr. John Cush RheumNow ( View Tweet)
Curious how COVID-19 affects rheumatic patients? Dr. Jeffrey Sparks ( @jeffsparks) is answering some top questions. #ACR20
https://t.co/Pd1gZa1o6f https://t.co/OVTqLeYI8q
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out this video with Dr. Dey (@DrMiniDey) on race/ethnicity associated with poor outcomes in rheum patients with COVID-19 ) #ACR20
https://t.co/ecenB2i5At
Links:
Dr. John Cush RheumNow ( View Tweet)
Listen to the Rheum Now podcast on Day 4 of the #ACR20 meeting.
Topics: Belimumab in Lupus Nephritis, Enthesitis in PsA, Equity & Inclusion in Rheumatology Education, Osteoarthritis Studies, Outcomes of COVID in Rheumatic Disease Patients
https://t.co/1PShHqXa0j https://t.co/9ALWsjWqpB
Links:
Dr. John Cush RheumNow ( View Tweet)
COVID, Artificial Intelligence and Metabolomics at #ACR20 with Dr. Arthur Kavanaugh.
Dr. Arthur Kavanaugh provides an overview of the ACR 2020 meeting, including his review of COVID, machine learning (AI) and metabolomics sessions.
https://t.co/AalXieuRfb
Links:
Dr. John Cush RheumNow ( View Tweet)
Watch our video: Outcomes for Rheumatic Disease Patients with COVID-19: Dr Kathryn Dao ( @KDAO2011) discusses plenary abstract #0430 presented Friday at the #ACR20 annual meeting.
https://t.co/QgD90Ea4Ft https://t.co/tQiwmxjayK
Links:
Dr. John Cush RheumNow ( View Tweet)
Pfizer vaccine data potentially shows >90% effectiveness via @nytimes https://t.co/jwVkmbMaTL
Dr Philip Robinson philipcrobinson ( View Tweet)
About half (51%) of patients from the FORWARD registry in the US had at least one telehealth appointment during COVID-19 pandemic and most were satisfied with the appointment @RheumNow #ACR20 Abstr#1962 https://t.co/z38ilD1n8Q
Dr. Antoni Chan synovialjoints ( View Tweet)
Summary of #ACR20 part A:
- HCQ is not a problem in rheumatic dz pts in terms of causing QTc prolongation
- Anti-phospholipid ab are found in a majority of hospitalized COVID19 pts — the most prevalent of which were anti-PST abs that are not in the of criteria for APS
@rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
What was the effect of COVID-19 in axSpA patients? From @rheum_cat In the early phase of COVID-19 there was a higher levels of stress and anxiety leading to higher BASDAI scores @RheumNow #ACR20 Abstr#1884
Dr. Antoni Chan synovialjoints ( View Tweet)
Tocilizumab NOT effective in preventing mechanical ventilation or death in moderately ill COVID-19 pts.
Double-blind, Placebo, RCT (n=243)
@RheumNow #ACR20 Abs#L07 #ACRbest https://t.co/juSQRCnTeD
Robert B Chao, MD doctorRBC ( View Tweet)
Does IL-6 blockade prevent mechanical ventilation or death in #COVID19? MGH study by Dr. Stone Abst#L07 graph shows no benefit @RheumNow #ACR20 https://t.co/DHfHYJCkod
Eric Dein ejdein1 ( View Tweet)
